<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested regimens for therapy of prosthetic valve endocarditis due to penicillin-susceptible viridans streptococci and &lt;EM innerHtml&gt;Streptococcus gallolyticus &lt;/EM&gt;(&lt;EM innerHtml&gt;bovis&lt;/EM&gt;) (MIC ≤0.12 mcg/mL)*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested regimens for therapy of prosthetic valve endocarditis due to penicillin-susceptible viridans streptococci and <em innerhtml="">Streptococcus gallolyticus </em>(<em innerhtml="">bovis</em>) (MIC ≤0.12 mcg/mL)*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested regimens for therapy of prosthetic valve endocarditis due to penicillin-susceptible viridans streptococci and <em innerhtml="">Streptococcus gallolyticus </em>(<em innerhtml="">bovis</em>) (MIC ≤0.12 mcg/mL)*</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="2">American Heart Association (AHA)</td> <td class="subtitle1">European Society of Cardiology (ESC)</td> </tr> <tr> <td class="subtitle2">Adult</td> <td class="subtitle2">Pediatric (not to exceed dose of normal adult)</td> <td class="subtitle2"><span class="sublist2_start"></span><span class="subtitle2">Adult</span> <span class="subtitle2_single"></span></td> </tr> <tr> <td> <p><strong>Either</strong></p> <p>Aqueous penicillin G 24 million units per 24 hours IV either continuously or in four or six divided doses for six weeks</p> <p><strong>or</strong></p> <p>Ampicillin 2 g IV every 4 hours for six weeks</p> <p><strong>or </strong></p> <p>Ceftriaxone<sup>¶</sup> 2 g per 24 hours IV in one dose for six weeks</p> <p><strong>with or without</strong></p> <p>Gentamicin<sup>Δ◊</sup> 3 mg/kg per 24 hours IV or IM in one dose for first two weeks</p> <p><strong><strong>Beta-lactam-intolerant patients:</strong></strong></p> <p>Vancomycin<sup>§</sup> 30 mg/kg per 24 hours IV in two divided doses for six weeks</p> </td> <td> <p><strong>Either</strong> </p> <p>Aqueous penicillin G 200,000 to 300,000 units/kg per 24 hours IV in six divided doses (maximum dose: 24 million units per 24 hours) for six weeks</p> <p><strong>or</strong></p> <p>Ampicillin 200 to 300 mg/kg per 24 hours IV divided in four or six divided doses (maximum dose: 12 g per 24 hours) for six weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone 100 mg/kg per 24 hours IV<sup>​</sup> in two divided doses or 80 mg/kg in one daily dose (maximum dose: 4 g per 24 hours; if dose is &gt;2 g per 24 hours, use divided dosing every 12 hours) for six weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup><span style="font-size: 13px;">Δ◊</span></sup> 3 to 6 mg/kg per 24 hours IV in three divided doses for first two weeks</p> <p><strong>Beta-lactam-intolerant patients:</strong></p> <p>Vancomycin<sup>§</sup> 40 mg/kg per 24 hours IV in two or three divided doses (maximum dose: 2 g per 24 hours unless levels are inappropriately low) for six weeks <strong>plus</strong> gentamicin (dosing as above) for first two weeks</p> </td> <td> <p><strong>Either</strong></p> <p>Aqueous penicillin G 12 to 18 million units per 24 hours IV in four or six divided doses or continuously for six weeks</p> <p><strong>or</strong></p> <p>Amoxicillin 100 to 200 mg/kg per 24 hours IV in four or six divided doses for six weeks</p> <p><strong>or</strong></p> <p>Ampicillin 12 g per 24 hours (or 100 to 200 mg/kg per 24 hours) IV in four or six divided doses for six weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>¶</sup> 2 g per 24 hours IV in one dose for six weeks</p> <p><strong>or</strong></p> <p>Vancomycin<sup>§</sup> 30 mg/kg per 24 hours IV in two divided doses for six weeks</p> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The doses above are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the individual Lexicomp drug monographs for renal dose adjustments.<br/>Wherever intramuscular administration is provided as an alternative, intravenous route is preferred, particularly in infants and children.</div><div class="graphic_footnotes">MIC: minimum inhibitory concentration; IV: intravenously; IM: intramuscularly.<br/>* AHA adult guidelines use MIC ≤0.12 mcg/mL; AHA pediatric guidelines use MIC ≤0.1 mcg/mL; ESC guidelines use MIC ≤0.125 mcg/mL.<br/>¶ Alternative in patients with nonsevere penicillin allergy; preferred for outpatient therapy.<br/>Δ Gentamicin should be omitted in patients with potential for nephrotoxicity, patients with creatinine clearance &lt;30 mL/min, or patients with impaired VIII cranial nerve function or severe decreased vision. In adults, aminoglycosides are dosed based on ideal body weight.<br/>◊ Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentration 3 to 4 mcg/mL, trough &lt;1 mcg/mL when two to three divided doses used; when given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per AHA guidelines, there is no role for measuring peak gentamicin concentration following single daily dosing.<br/>§ Vancomycin therapy only recommended for patients allergic to penicillins or cephalosporins. Penicillin desensitization can be attempted in stable patients. In adults, vancomycin is dosed based on actual body weight. The dose should be adjusted for trough concentration of 10 to 15 mcg/mL.</div><div class="graphic_reference">Data from:<br/><ol>
<li>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</li>
<li>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</li>
<li>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</li></ol></div><div id="graphicVersion">Graphic 61640 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
